Il Dong Pharmaceutical Co Ltd (249420) - Net Assets
Based on the latest financial reports, Il Dong Pharmaceutical Co Ltd (249420) has net assets worth ₩226.84 Billion KRW (≈ $153.72 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩573.88 Billion ≈ $388.91 Million USD) and total liabilities (₩347.04 Billion ≈ $235.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Il Dong Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩226.84 Billion |
| % of Total Assets | 39.53% |
| Annual Growth Rate | -6.33% |
| 5-Year Change | -37.51% |
| 10-Year Change | N/A |
| Growth Volatility | 16.07 |
Il Dong Pharmaceutical Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Il Dong Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 249420 total assets for the complete picture of this company's asset base.
Annual Net Assets for Il Dong Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual net assets of Il Dong Pharmaceutical Co Ltd from 2016 to 2024. For live valuation and market cap data, see Il Dong Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩159.06 Billion ≈ $107.79 Million |
-8.73% |
| 2023-12-31 | ₩174.27 Billion ≈ $118.10 Million |
-12.09% |
| 2022-12-31 | ₩198.22 Billion ≈ $134.33 Million |
+23.44% |
| 2021-12-31 | ₩160.58 Billion ≈ $108.83 Million |
-36.91% |
| 2020-12-31 | ₩254.55 Billion ≈ $172.50 Million |
+0.65% |
| 2019-12-31 | ₩252.89 Billion ≈ $171.38 Million |
-8.65% |
| 2018-12-31 | ₩276.82 Billion ≈ $187.60 Million |
-2.89% |
| 2017-12-31 | ₩285.07 Billion ≈ $193.19 Million |
+6.21% |
| 2016-12-31 | ₩268.41 Billion ≈ $181.90 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Il Dong Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 531.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩211.70 Billion | 131.69% |
| Total Equity | ₩160.76 Billion | 100.00% |
Il Dong Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Il Dong Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Changzhou Architectural Research Institute Group Co. Ltd. A
SHE:301115
|
$565.84 Million |
|
Wuhan Langold Real Estate Co Ltd
SHE:002305
|
$565.91 Million |
|
BETTERWARE DE MEXICO SAPI
F:BM0
|
$566.11 Million |
|
Hefei Kewell Power System Co Ltd
SHG:688551
|
$566.15 Million |
|
Duzhe Publishing & Media Corp
SHG:603999
|
$565.57 Million |
|
Mills Estruturas e Serviços de Engenharia S.A
SA:MILS3
|
$565.39 Million |
|
SNT Motiv Co Ltd
KO:064960
|
$565.33 Million |
|
Regulus Therapeutics Inc
NASDAQ:RGLS
|
$564.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Il Dong Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 169,542,721,080 to 160,758,267,270, a change of -8,784,453,810 (-5.2%).
- Net loss of 4,576,224,900 reduced equity.
- Dividend payments of 76,800,000 reduced retained earnings.
- Share repurchases of 173,160 reduced equity.
- Other factors decreased equity by 4,131,255,750.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-4.58 Billion | -2.85% |
| Dividends Paid | ₩76.80 Million | -0.05% |
| Share Repurchases | ₩173.16K | -0.0% |
| Other Changes | ₩-4.13 Billion | -2.57% |
| Total Change | ₩- | -5.18% |
Book Value vs Market Value Analysis
This analysis compares Il Dong Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.01x to 4.60x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩13178.05 | ₩26500.00 | x |
| 2018-12-31 | ₩12216.55 | ₩26500.00 | x |
| 2019-12-31 | ₩10630.38 | ₩26500.00 | x |
| 2020-12-31 | ₩10701.87 | ₩26500.00 | x |
| 2021-12-31 | ₩6428.69 | ₩26500.00 | x |
| 2022-12-31 | ₩7139.87 | ₩26500.00 | x |
| 2023-12-31 | ₩6129.58 | ₩26500.00 | x |
| 2024-12-31 | ₩5755.27 | ₩26500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Il Dong Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.74%
- • Asset Turnover: 1.04x
- • Equity Multiplier: 3.66x
- Recent ROE (-2.85%) is above the historical average (-20.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 4.69% | 6.25% | 0.37x | 2.05x | ₩-14.26 Billion |
| 2017 | 6.96% | 4.31% | 0.82x | 1.98x | ₩-8.67 Billion |
| 2018 | 4.60% | 2.52% | 0.89x | 2.04x | ₩-14.96 Billion |
| 2019 | -5.32% | -2.60% | 0.84x | 2.42x | ₩-38.73 Billion |
| 2020 | -5.11% | -2.32% | 0.93x | 2.38x | ₩-38.47 Billion |
| 2021 | -65.21% | -17.80% | 0.79x | 4.64x | ₩-115.00 Billion |
| 2022 | -74.03% | -22.20% | 0.97x | 3.43x | ₩-160.71 Billion |
| 2023 | -46.55% | -13.14% | 0.98x | 3.61x | ₩-95.88 Billion |
| 2024 | -2.85% | -0.74% | 1.04x | 3.66x | ₩-20.65 Billion |
Industry Comparison
This section compares Il Dong Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Il Dong Pharmaceutical Co Ltd (249420) | ₩226.84 Billion | 4.69% | 1.53x | $565.84 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Il Dong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central n… Read more